

cost effectiveness rosuvastatin

[\[PDF\] do you need a prescription for propecia uk](#)

[\[PDF\] erfahrungen orlistat ratiopharm](#)

[\[PDF\] want to buy viagra online](#)

[\[PDF\] cialis generico pagamento postepay](#)

[\[PDF\] generic form of actos](#)

[\[PDF\] cuanto salen las pastillas misoprostol](#)

[\[PDF\] renova shopping goiania](#)

Sensitivity analyses showed that the results were robust to variations in both statin efficacy and price. Patients aged 18 to 79 years with coronary heart disease CHD or equivalent who initiated treatment with atorvastatin, rosuvastatin, or simvastatin were included. Europe PMC requires Javascript to function effectively. A global Markov cohort model of primary and secondary CV prevention was developed and adapted to Brazilian and Colombian settings. Download full text in PDF Download. The risks and costs of major CV events and efficacy, adherence, and costs of statins were considered. Where rosuvastatin 10 mg did not dominate, ICERs ranged from 36 pounds sterling to pounds sterling per extra patient to goal. The objective of this study was to identify the most cost-effective statin or combination of statins, from the perspective of a managed care payer. Species Show all items. Chemicals Show all items. Read Article at publisher's site. Clinical evidence suggests that rosuvastatin is associated with slightly greater reductions in low-density lipoprotein cholesterol levels than is atorvastatin at comparable doses. Rosuvastatin dominates atorvastatin, pravastatin, and simvastatin because it is more effective and less costly, and it may be considered cost-effective compared with generic lovastatin. Conclusions In primary and secondary CV prevention, the efficacy advantage of rosuvastatin was minimal, while its acquisition cost was higher, particularly in Colombia. Under an Elsevier user license. Comparative Study. Journal Article lang:Clinicoecon Outcomes Res. ; doi: /CEOR.S Epub Jan Cost-effectiveness of rosuvastatin in comparison with generic atorvastatin and simvastatin in a Swedish population at high risk of cardiovascular events. Gandhi SK(1), Jensen MM, Fox KM, Smolen L, Olsson AG, Paulsson T. OBJECTIVE: This study assessed the long-term cost effectiveness of rosuvastatin therapy compared with placebo in reducing the incidence of major cardiovascular (CVD) events and mortality. METHODS: A probabilistic Monte Carlo simulation model estimated long-term cost effectiveness of rosuvastatin therapy (20 mg. Value Health. Nov-Dec;8(6) Cost-effectiveness of rosuvastatin compared with other statins from a managed care perspective. Benner JS(1), Smith TW, Klingman D, Tierce JC, Mullins CD, Pethick N, O'Donnell JC. Author information: (1)ValueMedics Research, LLC, Arlington, VA, and University of Maryland. Eur J Cardiovasc Prev Rehabil. Feb;12(1) Rosuvastatin is cost-effective in treating patients to low-density lipoprotein-cholesterol goals compared with atorvastatin, pravastatin and simvastatin: analysis of the STELLAR trial. Hirsch M(1), O'Donnell JC, Jones P. Author information: (1)AstraZeneca, Macclesfield. Nov 1, - Background: Assessments of the effectiveness and cost-effectiveness of treatment with statins in high-risk patients in routine clinical practice are needed. The objective of the present study was to estimate the clinical effectiveness and cost-effectiveness of rosuvastatin compared with atorvastatin or. Feb 15, - Cost-effectiveness analysis is a framework that gathers data on all these aspects of the treatment decision and weighs them to assess the value provided for the money spent. JUPITER (Justification for the Use of statins in Prevention: An Intervention Trial Evaluating Rosuvastatin) was a landmark. A decision-analytic model compared the cost-effectiveness of titration to goal with atorvastatin, fluvastatin, lovastatin, pravastatin, rosuvastatin, and simvastatin in patients with elevated low-density lipoprotein cholesterol (LDL-C). Effectiveness measures included the percentage change from baseline LDL-C and high-density. The incremental cost per quality-adjusted life-year gained for rosuvastatin versus atorvastatin was more than \$, and \$, in primary and secondary prevention, respectively. Brazilian analyses found lower incremental cost-effectiveness ratios for rosuvastatin at some dose comparisons due to similar pricing. It is cost-saving when compared to atorvastatin, but it increases costs when assessed against pravastatin and simvastatin (1, and per patient, respectively). Therefore, rosuvastatin is a dominant alternative compared to atorvastatin, having an incremental cost-effectiveness ratio of 30, to pravastatin and. Clinical data were obtained from the Statin Therapies for Elevated Lipid Levels Compared Across Doses to Rosuvastatin (STELLAR) trial. Drug costs were based on wholesale acquisition costs. Cost effectiveness was assessed with the net monetary benefit approach and a 1-year time horizon. Rosuvastatin at 10 mg, the.